title: Prognostic risk of atrial fibrillation in acute myocardial infarction complicated by left ventricular dysfunction: the OPTIMAAL experience.
abstract: OBJECTIVE
  The present study aimed to determine the frequency and the impact on clinical outcome of atrial fibrillation (AF) in patients with acute myocardial infarction (AMI) and left ventricular dysfunction.
  
  
  RESULTS
  In the OPTIMAAL trial, 5477 patients with AMI and signs of left ventricular dysfunction were included. At baseline, 655 patients (12%) had AF, and 345 (7.2%) developed new-onset AF during follow-up (2.7 +/- 0.9 years). Older patients, patients with history of angina and worse Killip class had and developed AF more frequently (P < 0.001). Patients with AF at baseline were at increased risk relative to those without AF for mortality [adjusted hazard ratio (HR) of 1.32, P = 0.001] and for stroke (HR 1.77, P < 0.001). New-onset AF was associated with increased subsequent mortality for the first 30 days following randomization (HR 3.83, P < 0.001) and the entire trial period (HR 1.82, P < 0.001). Risk of stroke was increased for the first 30 days (HR 14.6, P < 0.001) and for the whole trial period (HR 2.29, P < 0.001).
  
  
  CONCLUSIONS
  AF is frequently observed in patients with AMI complicated by heart failure. Current AF, and the development of new AF soon after AMI, is associated with increased risk of death and stroke.
authors.affiliation: Division of Cardiology, Helsinki University Central Hospital, Helsinki, Finland. mika.lehto@fimnet.fi
authors.forename: Mika
authors.initials: M
authors.lastname: Lehto
authors.forename: Steven
authors.initials: S
authors.lastname: Snapinn
authors.forename: Kenneth
authors.initials: K
authors.lastname: Dickstein
authors.forename: Karl
authors.initials: K
authors.lastname: Swedberg
authors.forename: Markku S
authors.initials: MS
authors.lastname: Nieminen
mesh_terms: D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000209:etiology*; D002216:Captopril / Q000627:therapeutic use; D004812:Epidemiologic Methods; D005260:Female; D006801:Humans; D019808:Losartan / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000150:complications* / Q000188:drug therapy; D011379:Prognosis; D020521:Stroke / Q000209:etiology; D018487:Ventricular Dysfunction, Left / Q000150:complications*
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000889:Anti-Arrhythmia Agents; D002216:Captopril; D019808:Losartan